Potential of soluble CD26 as a serum marker for colorectal cancer detection

Table 1 Performance characteristics of the sCD26 test

	Cohortn	CRC risk	sCD26cut-off(ng/mL)	CRC in sCD26+ patients	Advanced adenomas in sCD26+ patients	Polyps in sCD26+ patients	Other findings in sCD26+ patients	Sensitivity	Specificity
								(%)	(%)
1st Case-control study[89]	175	Diagnosed with CRC	410	99/110	-	-	6/110 Crohn´s; 1/110 GC	90% (CRC)	90% (CRC)
1st Case-finding study[97]	170	Average-risk	410	-	-ª	8/21	2/21 diverticula	-	-
2nd Case-finding study[95]	2673	Average- and increased-risk	410	2/140	4/1402	46/1402	12/140 diverticula	100% (CRC)1	89.9% (CRC)1
2nd Case-control study [94]	299	Increased-risk	460	27/110	20/110	13/110	18/110 IBD; 18/110 non-IBD; 14/110 anemia, diarrhea, rectal bleeding	81.8% (CRC); 58% (CN)	72.3% (CRC); 75.5 (CN)

n: Number of individuals; CR: Colorectal; CRC: Colorectal cancer; CN: Colorectal neoplasms including CRC and advanced adenomas; GC: Gastric cancer;IBD (inflammatory bowel diseases, includes colitis and Crohn’s); non-IBD (includes hemorrhoids and diverticula). ªNo data on polyps´ pathology could be obtained;

¹: Data obtained after one-year follow-up for the detection of interval cancers.

²: Pathological anatomy information obtained only for 16 of 46 polyps. The four advanced adenomas are also included in the polyps’ column.